Hemopexin in severe inflammation and infection: mouse models and human diseases

Tian Lin¹*, Dayana Maita², Sujatha R Thundivalappil², Frank E Riley², Jasmin Hambsch², Linda J Van Marter³, Helen A Christou³, Lorenzo Berra⁴, Shawn Fagan⁵, David C Christiani⁶ and H Shaw Warren⁷

Abstract

Introduction: Cell-free plasma hemoglobin is associated with poor outcome in patients with sepsis. Extracellular hemoglobin and secondarily released heme amplify inflammation in the presence of microbial TLR ligands and/or endogenous mediators. Hemopexin, a plasma protein that binds heme with extraordinary affinity, blocks these effects and has been proposed as a possible treatment approach to decrease inflammation in critically ill patients.

Methods: We studied mouse models of endotoxemia, burn wound infections and peritonitis in order to assess if a repletion strategy for hemopexin might be reasonable. We also measured hemopexin in small numbers of three patient populations that might be logical groups for hemopexin therapy: patients with sepsis and ARDS, patients with severe burns, and premature infants.

Results: Despite severe disease, mean plasma hemopexin levels were increased above baseline in each murine model. However, plasma hemopexin levels were decreased or markedly decreased in many patients in each of the three patient populations.

Conclusions: Potentially different behavior of hemopexin in mice and humans may be important to consider when utilizing murine models to represent acute human inflammatory diseases in which heme plays a role. The findings raise the possibility that decreased hemopexin could result in insufficiently neutralized or cleared heme in some patients with ARDS, burns, or in premature infants who might be candidates to benefit from hemopexin administration.

Introduction

Red blood cells (RBCs) are disrupted in multiple clinical settings, releasing hemoglobin and its breakdown product heme into tissues or the intravascular space. Free heme is toxic and may cause oxidizing injury and minor inflammation except in unusual circumstances [1,2]. In the presence of infection, extracellular hemoglobin and heme amplify inflammation by synergizing with microbial Toll-like receptor (TLR) agonists and non-microbial endogenous ligands, such as high-mobility group box 1 protein (HMGB1), to induce high levels of proinflammatory cytokines including tumor necrosis factor (TNF) and interleukin 6 (IL-6) [3-5].

Free hemoglobin is eliminated by binding to plasma protein haptoglobin and then transported into cells of monocytic lineage via receptor CD163 [6]. Free heme binds to a 60 kD plasma glycoprotein hemopexin (Hx) that has extraordinarily high affinity ($K_d <1$ pM) for heme, and then is transported into hepatocytes and macrophages via receptor CD91 [7]. Several lines of evidence have suggested that Hx could be beneficial in settings where infection and free heme coexist. First, Hx decreases the synergistic production of TNF and IL-6 from macrophages exposed to heme or hemoglobin together with lipopolysaccharide (LPS), Escherichia coli, Staphylococcus aureus or HMGB1 [3,5,8]. Second, Hx has been protective in mouse models of sepsis [8] and sickle cell anemia [9]. Third, elevated cell-free plasma hemoglobin [10,11] or decreased plasma Hx [8] is associated with increased mortality in sepsis. These studies support the concept that free hemoglobin and heme may drive or amplify tissue inflammation that might be suppressed by Hx, either through direct sequestering of free heme, or possibly indirectly through activation of heme oxygenase-1 (HO-1), inducing the production of anti-inflammatory CO.

* Correspondence: tlin7@mgh.harvard.edu

1Department of Pediatrics, Infectious Disease Unit, Massachusetts General Hospital, and Harvard Medical School, 149 13th Street, Charlestown, MA 02129, USA

Full list of author information is available at the end of the article

© 2015 Lin et al; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
and biliverdin [12,13]. Previous reports suggest that Hx is decreased in settings of hemolysis such as thalassemia and sickle cell disease [9,14]. However, much less is known about levels of Hx in inflammation or infection.

We measured plasma Hx concentrations in three diverse populations: patients with sepsis and acute respiratory distress syndrome (ARDS), patients with burns, and premature infants. These studies support the notion that there are some clinical settings in humans in which Hx is substantially depleted, paving the way for further studies in humans to investigate the potential therapeutic use of Hx to treat heme-amplified inflammation in infectious diseases. We also studied Hx in three mouse models: endotoxemia, burn wound infection, and peritonitis with fibrin and a blood clot. We found that mean Hx levels remained above baseline in each of the mouse models, suggesting that the study of heme-related pathophysiology in mouse models of infection may not reflect the human condition.

Methods
Materials
LPS from E. coli O55:B5 was purchased from List Biologicals (Campbell, CA, USA). E. coli O4:K54:H5 (CP9) was a gift from Tom Russo (University of Buffalo, Buffalo, NY, USA). Mouse hemoglobin was purified as described previously [3]. Fibrin and thrombin were purchased from Sigma-Aldrich (St. Louis, MO, USA).

Animal models
The animal studies were approved by the Massachusetts General Hospital (MGH) Institutional Animal Care and Use Committee. Six- to eight-week-old female C57BL/6 mice (Charles River Laboratories, Wilmington, MA, USA) were used in the studies.

Endotoxemia
Mice were injected via tail vein with 40 µg of LPS (2 mg/kg) or 4 mg of purified mouse hemoglobin or both in a volume of 200 µl, and were bled via tail vein at 24 hours before, 1 and 4 hours after the injection. Cardiac puncture was performed 24 hours after the injection.

Burn mouse model of gram-negative sepsis
The mouse burn wound infection model was performed as described previously [15], followed immediately by subcutaneous injection of E. coli O4 at log phase into the burned area as described. Blood was collected from the tail vein at different times, except the terminal bleed, which was done by cardiac puncture. Mice were given 400 µl saline intraperitoneally after tail vein bleeding. In separate experiments, we verified that baseline mouse Hx levels in blood obtained from a group of mice that underwent cardiac puncture were not statistically different than levels from a group of mice that had blood drawn from the tail vein (see Figure S1 in Additional file 1).

Peritonitis model of gram-negative sepsis
This model of sepsis due to peritonitis was adapted from Ahrenholz and Simmons as described previously [15,16]. Mice were implanted with a fibrin clot with or without E. coli O4 as desired or with 250 µl of blood in the peritoneum. All mice were administered 0.5 ml of saline intraperitoneally immediately following surgery. Some mice were given intramuscular injection of ceftriaxone (1 mg/mouse) 2 hours after the surgery. Blood was obtained by cardiac puncture 24 hours after surgery for determination of bacteremia (by culture of dilutions on Luria Broth agar plates) and for measuring Hx and cytokines in the plasma.

Human studies
All human studies were approved by the Partners Human Research Committee covering both Brigham and Women’s Hospital (BWH) and MGH. Blood samples were collected to make plasma by using BD vacutainer blood collection tubes with sodium heparin (Becton Dickinson and Company, Franklin Lakes, NJ, USA). All blood donors or patients except infants were aged between 18 and 40 years. All adult patients had a pre-existing central venous catheter for blood collection. Exclusion criteria included inability to obtain informed consent, pregnancy, and concurrent glucocorticoid or immunosuppressive treatment.

Control volunteer blood donors
Nine female and ten male healthy donors were recruited through the MGH and Partners clinical studies website. Additional inclusion criteria included a normal physical examination, a normal total hemoglobin concentration (>12.5 g/dl), and normal values of blood tests. Exclusion criteria included psychiatric disturbances, systemic disease, active smoking or less than 1 year of smoking cessation, alcohol use, any use of medications during the past 7 days, antibiotic use within 48 hours, and any type of cancer.

Adult patients with severe sepsis and ARDS
Blood samples were collected within 48 hours of diagnosis of sepsis and ARDS in 10 patients recruited from the MGH Surgical Intensive Care Unit. Additional inclusion criteria included clinical and laboratory diagnosis of the consensus definition of severe sepsis, ventilator dependence, and the diagnosis of ARDS made by the clinical team. Seven of the ten patients had a source of sepsis in the abdomen and one of the ten had had surgery.

Adult patients with severe burns
Blood samples were collected from five patients with severe burns (greater than 20% total body surface area) in
the Burn Unit at MGH on the day of administration (day 1) and days 3, 5 and then each week for 3 more weeks after admission to the hospital.

**Premature infants at various gestational ages**
Cord blood was collected immediately after the birth from 149 infants born at 23 to 25, 26 to 28, 29 to 31, 32 to 34, 35 to 37, and greater than 38 weeks that were enrolled in a study of cord blood vitamin D levels at BWH, Boston, MA, USA.

**Assays for hemopexin, heme, and cytokines**
Mouse and human plasma samples were saved at −80°C and assessed for Hx concentrations using enzyme-linked immunosorbent assay (ELISA) kits from GenWay Biotech Inc. (San Diego, CA, USA), heme concentrations by heme assay kits from BioVision Inc. (Milpitas, CA, USA), and TNF or IL-6 levels by ELISA kits from R&D Systems (Minneapolis, MN, USA).

**Statistics**
Data were analyzed by GraphPad Prism 6 (GraphPad Software, La Jolla, CA, USA). *P* <0.05 was considered to be statistically significant. D’Agostino-Pearson omnibus normality test was performed to assess the normality of the samples. Two-tailed unpaired *t* test was performed to compare two independent groups of samples of ARDS patients. To compare more than two samples, we performed analysis of repeated measures or ordinary one-way analysis of variance (ANOVA) for Gaussian distributed samples and Kruskal-Wallis tests for non-Gaussian distributed samples, respectively. To do pairwise comparisons, Donnett’s and Tukey’s tests were used for Gaussian and Dunn’s tests were used for non-Gaussian distributed samples. Pearson correlation analysis was performed for correlation studies of bacteremia with plasma IL-6 or Hx concentrations in the mouse peritonitis model.

**Results**

**Hx in mouse models**

**Endotoxemia**
Mice were injected with hemoglobin, LPS, or a mixture of both. Hemoglobin alone did not induce TNF. LPS induced the production of TNF, which was significantly enhanced by injection with LPS (data not shown), as has been previously described [17]. Hemoglobin alone did not have an effect on the levels of Hx in the plasma, but LPS with or without hemoglobin significantly increased Hx concentrations (Figure 1).

**Burn mouse model with gram-negative sepsis**
We studied Hx in a mouse burn wound infection model as described previously [15,16]. Plasma Hx concentrations increased by day 1 and became significantly increased on days 5, 7 and 9 after the burn and infection with *E. coli* O4 10^6 cfu/mouse (Figure 2). In mice with severe infections (*E. coli* O4 10^7 cfu/mouse injected), Hx was increased by day 1 and remained above baseline despite high bacteremia and high levels of IL-6. Eighty percent of these mice died. Mice with the lowest Hx levels survived the shortest time (data not shown).

**Peritonitis model of gram-negative sepsis**
In the peritonitis model with implantation of a peritoneal blood clot with or without *E. coli*, Hx levels increased at 24 hours by two- to threefold compared with controls.
after the sham surgery, and these levels were not different from those mice with surgery plus implantation of a blood clot with or without *E. coli* 10^4 cfu/mouse (Figure 3). Increasing the bacterial inoculation in the blood clot to 10^6 cfu/mouse significantly decreased the Hx levels compared to the clot with 10^4 cfu/mouse, although even with these high bacterial inocula the median Hx level remained above those of naïve mice. The decrease in Hx levels was not seen if the animals were administered ceftriaxone 2 hours after the surgery. We also found that bacteremia was strongly and positively correlated with IL-6 concentrations (Figure 4A). However, IL-6 levels were negatively correlated with Hx levels (Figure 4B).

**Hx in human conditions**

**Sepsis and ARDS**

Hx concentrations varied greatly in patients with sepsis and ARDS (Figure 5A). Two patients had very low levels of Hx compared to the control healthy donors (Figure 5B), and these two patients had elevated plasma heme concentrations (Figure 5C).

**Burn patients**

During the first week after admission to the burn center, Hx concentrations in patients with severe burns were significantly lower than levels in the control healthy blood donors. Levels slowly increased over the next 3 weeks (Figure 6A). Hx levels decreased again in two patients (patient 1 and 3) during episodes of sepsis (Figure 6B).

**Premature infants**

Hx concentrations in the cord blood of 149 infants at different gestational ages were much lower than in the 19 normal adult blood donors studied (shown as a mean by the dotted horizontal line) (Figure 7). Premature infants at different gestational ages had significantly lower Hx levels than those in infants delivered at gestational ages older than 38 weeks (*P* <0.001).

**Discussion**

The findings that heme and hemoglobin synergize with TLR agonists, bacteria and HMGB1 to amplify inflammation and this synergy is suppressed by Hx [3,5,8] raise the possibility of using Hx as a treatment in settings where free heme may be present in plasma or tissues in the presence of infection, especially in situations in which endogenous Hx is depleted. Here we investigated Hx concentrations in three different groups of patients that might be logical early target populations for clinical trials. The goal of these studies...
was to evaluate the range of Hx concentrations in each population to see if replenishment might be reasonable, rather than to attempt to correlate levels with outcome, which would require much larger studies.

We first studied patients with sepsis and ARDS. There is evidence of increased RBC and hemoglobin in intra-alveolar space in these patients [18], and in mice that received intratracheal injection of LPS [19]. We found that two patients had extremely low Hx levels (<250 μg/ml) and elevated heme levels, and the patient with the highest heme level died. The other patients had varied Hx levels. There have been two prior studies of Hx in patients with sepsis of all causes. One study found that decreased Hx correlated with increased mortality [8]. A different study also found that nonsurvivors had significantly lower Hx levels than survivors [20]. These findings are consistent with two recent studies that reported that elevated plasma hemoglobin correlates with mortality in patients with sepsis [10,11]. Patients in the intensive care unit who had elevated hemoglobin but without infection did not have increased mortality [11]. We are unaware of prior studies of Hx in patients with ARDS. Although our results suggest that Hx levels in patients with severe sepsis and ARDS vary markedly, a much larger study in this population will be needed to determine if Hx is predictive of poor outcome in patients with sepsis.

We also studied levels of Hx in five patients with severe burn injury. We found that Hx was depleted in all patients on admission, and that levels in all patients rose over a period of weeks but never above normal values during the hospital course. Hx levels in two patients decreased again during episodes of sepsis. We hypothesize that heme liberated into the tissues and blood during the acute burn injury led to temporary consumption. This is the first report of Hx levels in patients with burns.

The third clinical setting that we evaluated was premature infants. Very low birth weight infants have low levels of many plasma proteins, receive frequent blood transfusions, and have greater risk of infections than pediatric patients or adults. Premature birth is associated with a high rate of secondary morbidities, including acute and chronic lung disease, necrotizing enterocolitis, retinopathy, intraventricular hemorrhage, and intracranial white matter injury, virtually all of which have been linked with inflammation. Furthermore, the evolution of chronic lung disease and retinal changes of retinopathy of prematurity (RoP) are known to be associated with oxidant injury, and the risk of RoP appears to be reduced by restricting blood transfusion [21]. These and other complications associated with hemorrhage or hemolysis are likely to be related to or worsened by heme toxicity [22,23]. We found that all premature infants had strikingly low levels of Hx that gradually rose with gestational age. However, even at gestational ages greater than 38 weeks, all infants had much lower levels than adults. These findings are consistent with, and extend, the prior report of Kanakoudi et al. who reported in 1995 that Hx as measured by nephelometry was low in premature infants [24].

Our main finding that Hx is decreased in many patients in each setting we studied, in some cases markedly, suggest that a subset of patients with low Hx might benefit from Hx repletion as a therapy to decrease inflammation in infection amplified by free heme and hemoglobin. Most previous drugs that have been studied in attempts to treat infection-induced inflammation by blocking a wide variety of different aspects of the immune system have the potential side effect of immunocompromise [25]. One might expect that a repletion strategy with a plasma protein such as Hx would have low toxicity, and blocking excess heme seems unlikely to cause a deficit in immune function.
A mouse model system would be helpful to study details of roles of heme and Hx in infection-induced inflammation, as well as to aid in the development of Hx preparations for human use. We investigated mouse models for endotoxemia, burn injury, and sepsis induced by peritonitis because we were unable to find murine models that convincingly mimic aspects of sepsis-induced ARDS and premature infants. Concentrations of heme-pexin were maintained at or above the baseline level in most mice. Inoculation of very high numbers of bacteria resulted in decreased levels of Hx in some mice in the peritonitis model relative to those in sham mice, but mean levels remained above baseline. These findings are consistent with results obtained by Larsen and et al., that in a mouse sepsis model of cecal ligation and puncture (CLP), Hx concentrations were decreased relative to mice that had sham surgery, but were not much different than initial baseline levels [8]. The findings are also consistent with those reported by Spiller et al. that Hx is increased after mild CLP but not much different from baseline after severe CLP at later time points [26]. There is an increasing controversy as to how well mouse models of inflammation mimic human conditions, including in sepsis and burns, and a recent article proposed that it may be prudent to verify whether genes or gene products behave in a similar manner in mice and humans [27]. Some limitations in our study that could be factors in the appropriate comparison of our results in mice to humans include that we studied a

Figure 5 Plasma hemopexin and heme concentrations in patients with sepsis and acute respiratory distress syndrome (ARDS). Human hemopexin (hHx) concentrations were measured in 10 patients with sepsis and ARDS (1 to 10). (A) Horizontal lines represent medians. Data were analyzed by unpaired t-test. There is no significant difference between the two groups. (B) and (C) Bars represent hemopexin (B) and heme (C) in the plasma from individual patients and the mean of 19 healthy donors as the control (Ctrl, dotted line).

Figure 6 Plasma hemopexin concentrations of burn patients. Blood was drawn from 5 patients with severe burns at intervals up to 4 weeks on different days after admission to the hospital. Concentrations of human hemopexin (hHx) were measured in the plasma. Samples from 19 healthy donors were used as controls (Ctrl). (A) Data were analyzed by one-way analysis of variance (ANOVA) and Donnett’s test was done for comparisons to the control. Horizontal lines represent medians. *P <0.05; **P <0.01; ***P <0.001. (B) Bars represent the data from the individual patients (1 to 5) at the times in the same order shown in A. Dotted line represents the mean hHx concentration in the control sample (Ctrl).
single strain and gender of mice, that we studied mice of 6 to 8 weeks old compared to young adult patients, and that endotoxin challenge and peritoneal infection may not reflect sepsis causing ARDS.

Hx is an acute phase protein in several mammals, including mice, but is less of an acute phase protein in humans [28,29] so that inflammatory stimuli such as infection or tissue injury lead to only slightly elevated levels in humans. IL-6 is the main cytokine that induces the synthesis of Hx in hepatocytes during the acute phase response in mice [30]. We found that levels of IL-6 were positively correlated with the bacteremia as shown in other studies [31]. However, IL-6 was negatively correlated with Hx levels in mouse models in our studies, possibly due to hepatic dysfunction or the increased consumption of Hx by binding to increased free heme that outstripped production, or both.

Conclusions
Recent reports that plasma cell-free hemoglobin is associated with poor outcomes in sepsis [10,11], together with data that hemoglobin and heme are synergistic with microbial ligands to cause overactive inflammation [3], support the hypothesis that hemoglobin or secondarily released heme could be causative of immunopathology, and in turn that Hx might be therapeutic [8,9]. The data reported here that some adult patients with ARDS, most patients with burns, and most premature infants, have very low levels of Hx suggest the possibility that there may be inadequate neutralization or clearance of heme in some of these patients. Our results also suggest that it is difficult to mimic the human Hx dynamics in mouse inflammatory models and therefore it may be necessary to search for a different species to model the heme axis in human infections. A different approach might be to perform association studies in each of the three populations studied here to show plausibility. Then, if low Hx is associated with increased morbidity or mortality, it might be reasonable to show that a Hx product is safe, and then proceed directly to a treatment study using patients selected for high extracellular heme or low Hx levels.

Key messages
- Plasma hemopexin concentrations are decreased or markedly decreased in some patients with sepsis and acute respiratory distress syndrome, some patients with severe burns, and most premature infants. These results support the concept that there is a subset of patients in each population who might benefit from hemopexin repletion.
- Mean plasma hemopexin levels are increased above baseline in mouse models of endotoxemia, burn wound infection, and peritonitis-induced sepsis.
- The differing behavior of hemopexin in humans and mice in burns, and perhaps also in other inflammatory conditions, suggests that utilization of mouse models to study heme-related inflammation in humans should be done with caution.

Additional file
Additional file 1: Figure S1. Mouse hemopexin concentrations are not significantly different between plasma prepared from cardiac puncture and from tail vein bleeding. Blood was collected by cardiac puncture (CP, n = 15) or by tail vein bleeding (n = 32) from 6- to 8-week-old naive C57/BL6 mice. Mouse hemopexin levels were measured in the plasma. Data are inclusive from three pooled experiments for CP and from three pooled experiments for tail vein bleeds and are analyzed by unpaired t test. Horizontal lines represent medians. There is no significant difference between the CP and tail vein groups.

Abbreviations
ANOVA: analysis of variance; ARDS: acute respiratory distress syndrome; BWH: Brigham and Women’s Hospital; CLP: cecal ligation and puncture; ELISA: enzyme-linked immunosorbent assay; HMGBl: high-mobility group box 1 protein; HO-1: heme oxygenase-1; Hx: hemopexin; IL-6: interleukin 6; LPS: lipopolysaccharide; MGH: Massachusetts General Hospital; RBC: red blood cell; RoP: retinopathy of prematurity; TLR: Toll-like receptor; TNF: tumor necrosis factor.

Competing interests
In accordance with institutional policy, HSW has declared hemopexin to MGH as a potential candidate molecule to help decrease inflammation, and the institution has filed for patent protection. All the other authors have declared that no conflict of interest exists.
Acknowledgements

This work was supported by the National Institute of Health (grant number AI059010); the Shriners Hospital for Crippled Children (grant number 87200); the Assistance Foundation and Clinical Translational Science Award (UL1RR025758) to Harvard University and BWH from the National Center for Research Resources. This content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. We acknowledge the assistance of Maryelizabet Bilodeau in Division of Burns in MGH, and Marcia Filip and Yvonne Sheldon in BWH.

Author details

1. Department of Pediatrics, Infectious Disease Unit, Massachusetts General Hospital, and Harvard Medical School, 149 13th Street, Charlestown, MA 02129, USA. 2. Department of Pediatrics, Infectious Disease Unit, Massachusetts General Hospital, 149 13th Street, Charlestown, MA 02129, USA. 3. Department of Pediatric Newborn Medicine at Brigham and Women’s Hospital, and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. 4. Department of Anesthesiology, Critical Care and Pain Medicine, Massachusetts General Hospital, and Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA. 5. Department of Surgery, MGH Burn Service, Massachusetts General Hospital, and Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA. 6. Department of Medicine, Pulmonary and Critical Care Medicine, Massachusetts General Hospital, and Harvard Medical School, 149 13th Street, Charlestown, MA 02129, USA. 7. Department of Pediatrics and Medicine, Infectious Disease Unit, Massachusetts General Hospital, and Harvard Medical School, 149 13th Street, Charlestown, MA 02129, USA.

Received: 29 December 2014 Accepted: 16 March 2015

References

1. Dutra FF, Alves LS, Rodrigues D, Fernandez PL, de Oliveira RB, Golenbock DT, et al. Hemolysis-induced lethality involves inflammation activated by heme. Proc Natl Acad Sci U S A. 2014;111:E1110–8.
2. Ghosh S, Adisa OA, Chappa P, Tan F, Jackson KA, Archer DR, et al. Extracellular heme crisis triggers acute chest syndrome in sickle mice. J Clin Invest. 2013;123:4809–20.
3. Lin T, Kwak YH, Sammy F, He P, Thondvilappil S, Sun G, et al. Synergistic inflammation is induced by blood degradation products with microbial Toll-like receptor agonists and is blocked by hemopexin. J Infect Dis. 2010;202:624–32.
4. Fernandez PL, Dutra FF, Alves L, Figueiredo RT, Mourao-Sa D, Fortes GB, et al. Heme amplifies the innate immune response to microbial molecules through spleen tyrosine kinase (Syk)-dependent reactive oxygen species generation. J Biol Chem. 2010;285:52844–51.
5. Lin T, Sammy F, Yang H, Thondvilappil S, Hellman J, Tracey KJ, et al. Identification of hemopexin as an anti-inflammatory factor that inhibits synergy of hemoglobin with HMG1 in sterile and infectious inflammation. J Immunol. 2012;189:179–22.
6. Ascenzio P, Boccali A, Visca P, Altruda F, Beringhelli T, et al. Hemoglobin and heme scavenging. IUBMB Life. 2005;57:749–59.
7. Vakshtal Y, Maniack MJ, Hoskins G, Finkelstein JA, et al. Identification of the receptor scavenging hemopexin-heme complexes. Blood. 2005;106:2572–32.
8. Larsen R, Gazzino R, Jeney V, Tokaji L, Bozza FA, Japiassu AM, et al. A central role for free heme in the pathogenesis of severe sepsis. Sci Transl Med. 2010;2:51ra71.
9. Vinchi F, De Franceschi L, Ghigo A, Townes T, Cinino J, Silengo L, et al. Hemopexin therapy improves cardiovascular function by preventing heme-induced endothelial toxicity in mouse models of hemolytic diseases. Circulation. 2013;127:1317–29.
10. Jahn DR, Bastarache JA, Peterson JF, Sills G, Wickersham N, May AK, et al. Association between cell-free hemoglobin, actinaminopenia, and mortality in patients with sepsis: an observational study. Crit Care Med. 2013;41:784–90.
11. Adarozk M, Hamburge T, Petrut F, Peters J, de Greef H, Hartmann M, Freden. Hemoglobin concentration in severe sepsis: methods of measurement and prediction of outcome. Crit Care. 2012;16:R125.
12. Chung SW, Liu X, Macias AA, Baron RM, Perella MA. Heme oxygenase-1 derived carbon monoxide enhances the host defense response to microbial sepsis in mice. J Clin Invest. 2008;118:239–47.
13. Pampolina A, Ferreira A, Balla J, Jeney V, Balla G, Epiphanio S, et al. Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria. Nat Med. 2007;13:703–10.
14. Muller-Eberhard U, Javid I, Liem HH, Hanstein A, Hanna M. Plasma concentrations of hemopexin, haptoglobin and heme in patients with various hemolytic diseases. Blood. 1968;32:81–5.
15. Valentine CR, Hellman J, Beasley-Toppiffe LK, Bagchi A, Warren HS. Passive immunization to outer membrane proteins MLP and PAL does not protect mice from sepsis. Mol Med. 2006;12:2522–8.
16. Stevens EJ, Ryan CM, Friedberg JS, Barnhill RL, Yarmush ML, Tompkins RG. A quantitative model of invasive Pseudomonas infection in burn injury. J Burn Care Rehabil. 1994;15:232–5.
17. Su D, Roth R, Levin J. Hemoglobin infusion augments the tumor necrosis factor response to bacterial endotoxin (lipopolysaccharide) in mice. Crit Care Med. 1999;27:771–8.
18. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet. 1967;2:319–23.
19. Bastarache JA, Sebag SC, Clune JK, Grove BS, Lawson WE, Janz DR, et al. Low levels of tissue factor lead to alveolar haemorrhage, potentiating murine acute lung injury and oxidative stress. Thorax. 2012;67:1032–9.
20. Janz DR, Bastarache JA, Sills G, Wickersham N, May AK, Bernard GR, et al. Association between haptoglobin, hemopexin and mortality in adults with sepsis. Crit Care. 2013;17:R72.
21. Del Vecchio A, Henny E, D’Amato G, Cannuscio A, Coriello L, Motta M, et al. Instituting a program to reduce the erythrocyte transfusion rate was accompanied by reductions in the incidence of bronchopulmonary dysplasia, retinopathy of prematurity and necrotizing enterocolitis. J Matern Fetal Neonatal Med. 2013;26:77–9.
22. Paul DA, Mackley A, Novitsky A, Zhao Y, Brooks A, Locke RG. Increased odds of necrotizing enterocolitis after transfusion of red blood cells in premature infants. Pediatrics. 2011;127:E345–41.
23. McGrady GA, Retig P, Iste GR, Jason JM, Holman RC, Evatt BL. An outbreak of necrotizing enterocolitis. Association with transfusions of packed red blood cells. Am J Epidemol. 1987;126:1165–72.
24. Kanakoudi F, Drossou V, Tzoumoul V, Diamanti E, Konstantidiss T, Gerensis A, et al. Serum concentrations of 10 acute-phase proteins in healthy term and preterm infants from birth to age 6 months. Clin Chem. 1995;41:605–8.
25. Fink MP, Warren HS. Strategies to improve drug development for sepsis. Nat Rev Drug Discov. 2014;13:541–58.
26. Spiller F, Costa C, Souto FO, Vinchi F, Mestiner FL, Laure HJ, et al. Inhibition of neutrophil migration by hemopexin leads to increased mortality due to sepsis in mice. Am J Respir Crit Care Med. 2011;183:922–31.
27. Seck J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A. 2013;110:3507–12.
28. Muller-Eberhard U. Hemopexin Methods Enzymol. 1988;163:536–65.
29. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990;265:621–36.
30. Immenschuh S, Song DX, Sato H, Muller-Eberhard U. The type II interleukin-6 response element predominates the transcriptional regulation of the hemopexin acute phase responsiveness. Biochem Biophys Res Commun. 1995;207:922–7.
31. Immenschuh S, Song DX, Sato H, Muller-Eberhard U. The type II interleukin-6 response element predominates the transcriptional regulation of the hemopexin acute phase responsiveness. Biochem Biophys Res Commun. 1995;207:922–7.
32. Diepold M, Noellke P, Duffner U, Konny U, Berner R. Performance of Interleukin-6 and Interleukin-8 serum levels in pediatric oncology patients with neutropenia and fever for the assessment of low-risk. BMC Infect Dis. 2008;8:28.